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Inosine triphosphate pyrophosphatase (ITPase) catalyzes the conversion of inosine triphosphate (ITP) to the correspondent monophosphate.
The ITPA c.94C>A and g.IVS2+21A>C allelic variants are associated with decreased red cell enzyme activity. The ITPA c.94C>A [P32T]
sequence variant is associated with an increased risk of adverse drug reactions in patients treated with the thiopurine drug azathioprine. The aim of
this study was to explore the molecular mechanisms of ITPase deficiency. ITPA mRNA was extracted from peripheral blood leukocytes (PBL),
Epstein–Barr virus transformed lymphoblast cell cultures, reticulocytes, and cultured fibroblast from patients with known ITPA genotypes. ITPA
mRNA was reversed transcribed, sequenced and the relative amounts of misspliced transcripts quantitated from three independent experiments.
The ITPA g.IVS2+21A>C sequence variant resulted in missplicing of exon 3. The ITPA c.94C>A allelic variant resulted in missplicing of exons
2 and 3 representing, in PBL samples, 61% of the total mRNA expressed in ITPA c.94C>A homozygotes. We proposed that the ITPA c.94C>A
allelic variant destroys an exonic splicing silencing (ESS) element in exon 2, resulting in the activation of two nearby upstream 5′ splice sites and
missplicing of the exons 2 and 3 cassette causing structural changes to the enzyme and contributing to ITPase deficiency.
© 2006 Elsevier B.V. All rights reserved.Keywords: ITPA; ITPase, Inosine triphosphate pyrophosphatase; Azathioprine; ADR, Adverse drug reaction; Pharmacogenetic; Cryptic 5′ splice site; Missplicing1. Introduction
The cytosolic enzyme ITPase (EC 3.6.1.19) catalyses the
hydrolysis of ITP to inosine monophosphate (IMP). ITPase
deficiency is a benign red cell enzymopathy marked by the
accumulation of ITP in red cells [1]. ITPase is ubiquitously
expressed although activity differs according to cell type [2]. Its
function is not clearly understood but possible roles for ITPase
could be to prevent the accumulation of rogue nucleotides [3]
which would be otherwise incorporated into DNA and RNA, or
compete with nucleotides such as GTP in signalling processes.
ITPase might also regulate intracellular ATP pools [4] through
the IMP intermediate.⁎ Corresponding author. Tel.: +44 207 188 1265; fax: +44 207 188 1280.
E-mail address: tony.marinaki@kcl.ac.uk (A. Marinaki).
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doi:10.1016/j.bbadis.2006.10.006ITPase deficiency is polymorphic. An early population study
showed that ∼5% of a normal population have decreased
ITPase activity resulting in a bimodal activity distribution [5].
Accumulation of high levels of endogenous ITP, in the red cells
of completely ITPase deficient individuals, was first demon-
strated by Vanderheiden in 1964 [6].
The ITPA gene, GenBank accession number AF026816, is
located on the short arm of chromosome 20 (20p13) [7]. Lin
et al. [8] isolated a cDNA clone encoding human ITPase, and
subsequently, Sumi et al. [9] determined the genomic
structure of the ITPA gene which consists of eight exons
and is ∼13 kb long. In a Caucasian population, two allelic
variants in the ITPA gene were associated with decreased
ITPase enzyme activity, ITPA c.94C>A [P32T] in exon 2,
and ITPA g.IVS2+21A>C [9]. Homozygotes for the ITPA
c.94C>A mutation had zero red cell enzyme activity, whereas
enzyme activity in heterozygotes was 22.5% of the control
Table 1
The effect of different ITPA genotypes on mRNA transcript level in different cell















hom/wt PBL 69% 0% 31%
hom/wt PBL 56% 1% 43%
hom/wt PBL 58% 0% 42%
het/wt PBL 32% 1% 67%
het/het PBL 44% 4% 52%
wt/hom PBL 12% 16% 72%
wt/het PBL 15% 5% 80%
wt/wt PBL 25% 5% 70%
wt/wt PBL 14% 4% 82%
wt/het Reticulocytes 25% 5% 70%
wt/wt Reticulocytes 8% 0% 92%
het/wt Lymphoblasts 36% 1% 63%
het/wt Lymphoblasts 41% 0% 59%
wt/wt Fibroblasts 1% 2% 97%
wt/wt Fibroblasts 1% 5% 94%
wt=wild-type, het=heterozygous, hom=homozygous, PBL=peripheral blood
leukocytes.
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of a dimeric enzyme. Patients heterozygous for the ITPA
g.IVS2+21A>C allelic variant had ITPase enzyme activity
which averaged 60% of the control mean, while compound
heterozygotes for the ITPA c.94C>A and g.IVS2+21 A>C
allelic variants had 10% residual activity. Recently, two
studies have identified different mutations at the same
position in intron two of the ITPA gene, g.IVS2+68T>G
[10] in a Japanese patient with decreased enzyme activity,
and g.IVS2+68T>C [11].
Although ITPase deficiency has not been associated with any
disease or clinical condition, it was hypothesized that dele-
terious effects might be observed only under certain conditions
of metabolic stress. It was also suggested that ITPase deficient
patients treated with purine drug analogues such as thiopurines,
would be at risk of suffering from side effects [1]. ITPase has a
broad substrate affinity for both purines (ITP, dITP, XTP) and
pyrimidines (UTP) [8]. This locus is therefore of particular
interest from a pharmacogenetic point of view. In a retrospective
study of inflammatory bowel disease (IBD) patients treated with
azathioprine (AZA), we reported a significant association
between the ITPA c.94C>A allelic variant and adverse drug
reactions (ADR) such as flu-like symptoms, rash and
pancreatitis [12]. Recently, a prospective clinical trial of IBD
patients treated with AZA, showed that patients with the ITPA
c.94C>A allelic variant were significantly more likely to be
withdrawn from therapy due to ADR [13]. Another study has
shown that AZA-related leucopenia observed in IBD patients on
AZA was significantly associated with the ITPA c.94C>A
allelic variant [14]. However, others studies have shown no
association between variant ITPA genotypes and adverse
reactions to AZA therapy [15,16].
The mechanism behind the loss of enzyme activity due to the
ITPA c.94C>A allelic variant is not known. We previously
proposed that the amino acid substitution P32T may affect
enzyme function by impairing dimer formation between wild-
type and variant subunits. It was also proposed that the ITPA g.
IVS2+21A>C allelic variant altered a branch point resulting in
abnormal mRNA splicing [9].
Pre-mRNA splicing is an essential step that leads to the
removal of introns from RNA. Spliceosome assembly and
splicing efficiency are guided by the presence of conserved
sequences in the pre-mRNA, such as the 5′ and 3′ splice sites,
and the branch site. The 5′ splice site (5′ss) conserved sequence
is recognized by the U1 small nuclear (snRNA) 5′ terminus
[17], guiding the first step in spliceosome assembly. In addition
to these conserved sequences, introns and exons have sequence
elements, exonic/intronic splicing enhancers (ESE/ISE) and
exonic/intronic splicing silencers (ESS/ISS), which are binding
sites for Serine Rich proteins (SR) and heterogeneous nuclear
ribonucleoprotein (hnRNP). The binding of these proteins will
enhance or inhibit splicing.
At least 15% of disease-associated point mutations result in
abnormal pre-mRNA splicing [18]. Furthermore, 74% of
human genes have been reported to be alternatively spliced
[19]. Alternative pre-mRNA splicing is a way for eukaryotic
cells to regulate gene expression and generate a wide array ofprotein isoforms, affecting protein activity and localization in
the cell [20].
The aim of this study was to further investigate the effect of
ITPA gene allelic variants on ITPase mRNA splicing.
2. Materials and methods
Ethical approval was received from Guy’s and St. Thomas’ ethics
committee. EDTA blood was drawn by veno-puncture after informed consent.
In order to investigate ITPA mRNA missplicing, total RNA was rapidly
extracted using Total RNA Isolation Reagent (Invitrogen Ltd., Paisley, UK)
from peripheral blood leucocytes (PBL) (n=9), Epstein–Barr virus (EBV)
transformed lymphoblasts (n=2), reticulocytes (n=2), and fibroblasts (n=2),
with known ITPA genotypes (Table 1) and single strand cDNA synthesized
using an oligo dT15 primer and Moloney murine leukaemia virus (MMLV)
reverse transcriptase (Invitrogen Ltd., Paisley, UK). The ITPA cDNA coding
region was amplified in two rounds of PCR using outer 34forward-
CCAGCCGGAAGTTTTCTGTCAC and 814reverse-CAGACAGGCCGGT-
GAGGCTAC primers, and nested 49forward-CTGTCACTGGACGCC-
AAGGAG and 779reverse-AAAGGGGAAACCCTGAAGGAAG primers.
Thermocycler conditions were 40× (94 °C 1 min, 54 °C 30 sec, 72 °C 1 min)
and 30× (94 °C 1 min, 54 °C 30 sec, 72 °C 1 min) for outer and nested primers,
respectively. PCR products were gel purified and sequenced on an ABI 377
Sequencer using the ABI PRISM®BigDye™ Terminator Cycle Sequencing
Ready Reaction Kit v1.1 (Applied Biosystems, Foster City, USA). To quantitate
ITPA mRNA misspliced transcripts, ITPA cDNA was amplified from the outer
PCR product with 49forward and 386reverse-TGGTGGAGACCTT-
CAGGCTTTAAC-TET nested primers. Thermocycler conditions were as fo-
llows 30× (94 °C 1 min, 55 °C 30 s, 72 °C 45 s). Relative quantification of the
amount of ITPA mRNA misspliced transcripts was carried out on an ABI 377
sequencer using GeneScan fragment analysis software v2.0.2. This technique
allowed misspliced ITPA mRNA to be sized to 1 bp relative to a PRISMTM-
GeneScan-500 TAMRA internal standard (Applied Biosystems, Foster City,
USA) as previously described [21], and quantified. The fluorescent label on the
reverse primer allowed accurate quantitation of the cDNA transcripts by peak
area as described and validated by others [22]. Duplicate determinations were
carried out in three independent experiments. Peak areas for each ITPA cDNA
transcript were then expressed as a percentage of the total ITPA transcripts. One
way analysis of variance (ANOVA), Bonferroni, and Dunn’s multiple
comparison tests were used to test for significant differences between genotypes.
Fig. 1. (A) ITPA genotype and ITPA mRNA missplicing in peripheral blood leukocytes, (B) ITPA genotype and mRNA missplicing in fibroblasts, reticulocytes and
cultured lymphoblasts. ITPA cDNA amplification gave fragments of 361 bp (full length mRNA transcript Type 1) and 238 bp (exons 2 and 3 spliced out, transcript
Type 2) in length. The ITPA c.94C>A/g.IVS2+21A>C genotypes are shown above each lane. (A) Lanes 1–9: peripheral blood leukocytes. Lane 10: 100 bp DNA
Ladder marker. (B) Lanes 1 and 2: reticulocytes. Lanes 3 and 4: cultured lymphoblasts. Lanes 5 and 6: fibroblasts. Lane 7: 100 bp DNA Ladder marker. Wt=wild-type,
het=heterozygous, hom=homozygous.
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ebi.ac.uk/asd-srv/wb.cgi, and http://cubweb.biology.columbia.edu/pesx/ were
used to search for exonic splicing enhancer/silencer (ESE/ESS) and intronic
splicing enhancer/silencer (ISE/ISS) sequence motifs. http://www.ncbi.nlm.nih.
gov/dbEST/ was used to search for alternative spliced forms of ITPA mRNA
clones.
3. Results
ITPA cDNA from patients with various ITPA genotypes were
analyzed (Table 1). PCR products resulting from the amplifica-
tion of the full length ITPA mRNAwith nested primers yielded
two different fragments, a high molecular weight (HMW) band,
which corresponded in size to the predicted ITPA mRNA full
length transcript of 751 bp with exons 1–8, and an unexpected
low molecular weight (LMW) band of ∼600 bp. Both bands
were gel purified and sequenced. The HMW band correspondedFig. 2. Detail of ITPA cDNA sequences. (A) ITPA cDNA sequence of the high mole
transcript (Type 1). (B) ITPA cDNA sequence of the low molecular weight band (238
(Type 2).in sequence to the full length transcript (Type 1). Sequencing of
the LMW band showed a cDNA transcript with a deletion of
exons 2 and 3 (Type 2) (Fig. 2).
To quantify the relative amounts of ITPAType 1 and Type 2
transcripts, the outer primer (34forward and 814reverse) PCR
products, were amplified with the nested primers (49forward
and 386reverse), with the reverse primer located in exon 4. Two
bands were observed on the gel, a HMW band corresponding to
the Type 1 transcript with a predicted size of 361 bp, and a
LMW band corresponding to the Type 2 transcript with a
predicted size of 238 bp. It was observed that the intensity of the
band corresponding to the Type 2 transcript varied with
genotype, with the highest proportion seen in ITPA c.94C>A
homozygous genotypes (Fig. 1). However, low levels of the
Type 2 transcript were also observed in wild-type PBL. The
386reverse primer was synthesized with a fluorescent labelcular weight band (361 bp) corresponding to the normally spliced ITPA mRNA
bp) corresponding to the ITPA mRNA transcript with exons 2 and 3 spliced out
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detected and quantified. Three fragments were detected, a full
length fragment (361 bp) and two other fragments of 238 bp and
296 bp. The 238 bp fragment corresponded in size to the Type 2
transcript with exons 2 and 3 spliced out, whereas the 296 bp
fragment had the predicted size of a transcript lacking exon 3
only, and was designated a Type 3 transcript. The relative
amounts of misspliced transcripts as a percentage of total ITPA
transcription in various ITPA genotypes are summarized in
Table 1.
The highest percentage of Type 2 transcripts was observed in
ITPA c.94C>A homozygotes (Table 1). In PBL this represented
on average 61% (61.3±8.2, mean±SD) of the total ITPA
mRNA expressed, which was significantly different (P<0.001)
from the 39% (39±7.9) observed in heterozygotes and the 17%
(16.9±8.6) in wild-types (P<0.001). Both of the lymphoblast
samples analyzed were heterozygous for the ITPA c.94C>A
alteration with 38% of the misspliced Type 2 transcript, similar
to the result obtained for PBL samples with a heterozygous
genotype. Reticulocyte samples were wild-type for the ITPA
c.94C>A mutation, and had 16% of the misspliced Type 2
transcript, a result in accordance with that obtained for the ITPA
c.94 C>A wild-type homozygous genotype in PBL. Wild-type
fibroblasts showed the most striking difference when compared
to the other wild-type cell types, only 1% of misspliced Type 2
transcript was observed (Fig. 2).
The Type 3 transcript was present at low levels (1–5%) in all
patients with a wild-type genotype for ITPA c.94C>A and g.
IVS2+21A>C. The proportion of this transcript increased to
16% in one patient homozygous for the g.IVS2+21A>C
mutation, which was significantly different from the wild-type
genotype (P<0.05, Dunn’s multiple comparison test), suggest-
ing that this allelic variant causes missplicing of exon 3.
4. Discussion
At least 15% of human genetic diseases are due to mutations
in consensus splice site sequences such as the 5′ss (C/A)AG|
GURAGU, the 3′ splice site (3′ss) consensus sequence YAG|G,
the branch point sequence, YNYURAY and mutations present
in ESE/ISE, and ESS/ISS elements [18,20,23]. ESE/ESS and
ISE/ISS are highly variable sequences in the pre-mRNA that
enhance or reduce the efficiency of splicing. ESE and ESS
sequences are binding sites for SR and hnRNP proteins,
respectively, which are essential components of the splicing
machinery. The balance between these elements determines the
strength of exons and introns.
This study has shown that the putative branch site mutation
ITPA g.IVS2+21A>C results in missplicing of exon 3 only.
Furthermore, the results reported in this study show that although
the ITPA c.94C>A alteration is located in the coding region of the
ITPA gene, and results in the amino acid substitution P32T, the
mutation also results in ITPAmRNAmissplicing of exons 2 and 3.
The ITPAType 2 transcript (exons 2 and 3 spliced out) constituted
17% on average of total mRNA transcripts in ITPA c.94C>A
wild-type PBL, levels increased to 39% for ITPA c.94C>A
heterozygotes, and 61% for variant homozygotes.It was postulated that the ITPA g.IVS2+21A>C mutation in
intron 2 altered the conserved adenine of a putative branch site
causing missplicing of exon 3 [9] resulting in 60% residual
activity in the heterozygous genotype. A study reported by
Heller et al. [24] concluded that the ITPA g.IVS2+21A>C
allelic variant had a lower splicing efficiency compared to the
wild-type allele confirming that missplicing was the molecular
basis underlying the low enzyme activity associated with this
mutation. Heller et al. argued that the long distance between the
g.IVS2+21A>C mutation and the putative down stream splice
acceptor site provided an unlikely mechanism for a branch point
effect [9], and proposed instead that the mutation altered an
extended conserved splice site consensus region next to the
exon–intron junction. But, although branch points are normally
located 20–40 nucleotides upstream of the 3′ ss, some studies
have reported distances >150 nucleotides upstream. For
example, the branch point of intron 2 of the alpha-tropomyosin
gene is located at an unusual position 177 nucleotides upstream
of the 3′ acceptor splice site, only 42 nucleotides from the exon
2 donor splice site [25]. It was also shown that splicing of exons
5 to 7 in the rat tropomyosin 1 gene was associated with the use
of one of three adenine residues located at positions 144, 147
and 153 upstream of the 3′ splice acceptor site [26]. Therefore,
the branch point does not exclusively need to be close to the 3′
splice acceptor site. Other putative branch sites are present
along the intron. Consequently, it is likely that the ITPA g.IVS2+
21A>C alteration destroys a preferred adenine branch point
inhibiting lariat formation and intron 2 splicing.
How the ITPA c.94C>A mutation causes skipping of exons
2 and 3 was not clear. We studied the possibility that this
mutation affects splicing by altering ESE or ESS sequence
motifs recognized by SR or hnRNP proteins. This was analyzed
using different motif finders available on the web. The first
finder searched http://www.ebi.ac.uk/asd-srv/wb.cgi/, gives
information about ESE/ESS, and ISE/ISS sequence elements.
A search using the ITPA c.94C>A wild-type sequence showed
that the mutation is located in an exonic enhancer element
recognized by SC35 (AGTTTCCA). When the same search was
performed with the variant sequence, the site was recognized by
two SR proteins, SRp40 (TACATG) and SRp55 (TTACATG-
CACTTT) which are also exonic splicing enhancers. The
second finder, http://rulai.cshl.edu/cgi-bin/tools/ESE/esefinder.
cgi/, focuses only on exonic splicing enhancer elements. With
this finder, no enhancer elements were identified which
included the ITPA c.94C>A wild-type sequence, although the
variant sequence was recognized by SRp40 (TTACATG) and
SRp55 (TACATG).The third finder, http://cubweb.biology.
columbia.edu/pesx/, identifies putative ESE/ESS and ISE/ISS
sequence motifs recognizable by SR and hnRNP proteins. This
finder showed that two ESS elements were destroyed when the
mutation was present (Fig. 3).
Exon 2 of the ITPA gene has two cryptic 5′ss at positions
−35 and −19 relative to the authentic 5′ss at position +1 in
intron 2 (Fig. 4). None of the ITPA exon 2 cryptic 5′ss, nor the
authentic splice site, share complete homology with the 5′ss
consensus sequence as shown in Fig. 4., therefore, the three 5′ss
can be considered as weak sites needing upstream enhancer
Fig. 3. Location of ESE/ESS, and ISE/ISS sequence motifs on exon 2, intron 2
and exon 3 of the ITPA wild-type gene. Exons are represented in uppercase.
Green sequences denote ESE/ISE. Red sequences denote ESS/ISS. The ITPA
c.94C>A mutation is shown in a larger uppercase font. The first bases of ESE/
ISE and ESS/ISS are underlined. The ITPA 94C wild-type sequence is a binding
site for a silencer. When the ITPA 94A mutation is present, the silencer is
destroyed. Data obtained from http://cubweb.biology.columbia.edu/pesx/.
ESE/ISE=exonic/intronic splicing enhancers, ESS/ISS=exonic/intronic spli-
cing silencers.
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sequence, the choice of the authentic 5′ss in preference to the
cryptic sites may be explained by the presence of a silencing
element which inactivates the two cryptic 5′ss at −35 and −19.
When the ITPA c.94C>A mutation is present, the ESS is
destroyed and one or both of the cryptic 5′ss may be activated. It
is known that when U1 snRNP does not bind stably to any
splice site, all the weak sites compete with each other [28].
Furthermore, the mutation introduces a sequence element
recognized by two SR proteins (SRp40, SRp55), and the
presence of these elements may increase the chances of cryptic
splice site utilization. In addition, exon 2 of the ITPA gene is
small (58 bp). The close proximity of splice sites on either side
of small exons is hypothesized to introduce stearic interference
between bound splicing factors [20] and has been related to
inefficient splicing of some small exons [29]. The use of any of
the cryptic 5′ss is likely to decrease even further the length ofFig. 4. Portion of the ITPA gene showing cryptic 5′ splice sites (5′ss). Exon 2 is repres
(ESS) element is shown in red. The ITPA c.94C>A allelic variant is shown in a larg
underlined. Arrow number 3 shows the authentic 5′ss, arrows 1 and 2 point to two cry
et al. [32]. The size of each base represents its frequency.exon 2 and the splicing efficiency of this exon. Interference
between splice sites may also explain the presence of the Type 2
transcript in wild-type patients.
The activation of cryptic 5′ss has been addressed in several
studies. Thalassemia-associated point mutations in intron 1
position +1 and +5 activate three cryptic neighboring 5′ss at
positions −38, −16 (within the exon) and +13 (within the
intron) [28]. More recently, a novel mutation in the E1α PDH
(pyruvate dehydrogenase) gene located downstream of exon 7
has been shown to activate a cryptic splice donor site leading to
retention of intronic sequences through increased binding of
SC35 to the mutated sequence [27].
ITPAmRNA missplicing of exons 2 and 3 (transcript Type 2)
does not generate a frameshift, however skipping of exon 2 or 3
alone is predicted to result in a frameshift raising the possibility
of nonsense mediated decay (NMD). A fragment corresponding
to a deletion of exon 3 only (transcript Type 3) was observed in
ITPA g.IVS2+21A>C variant genotypes at a low percentage by
the sensitive fluorescent system. Levels of Type 3 transcripts in
ITPA g.IVS2+21A>C heterozygotes did not correlate with the
40% reduction in enzyme activity phenotype. The low percen-
tage of misspliced mRNA lacking exon 3 is consistent with the
NMD of a frameshifted transcript.
No ITPA mRNA corresponding to a deletion of exon 2 only
was seen in the ITPA c.94C>Avariant, implying that splicing of
exon 3 is dependent on the splicing of exon 2. Hence factors
affecting splicing of exon 2 will lead to the generation of
transcripts lacking both exons 2 and 3. By contrast, missplicing
of exon 3 associated with the ITPA g.IVS2+21A>C mutation
did not influence splicing of other exons.
Due to the high levels of Type 2 transcripts observed in wild-
type samples (17%), the GenBank Expressed Sequence Tags
data base (dbEST) (http://www.ncbi.nlm.nih.gov/dbEST/) was
searched for alternative spliced forms of ITPA mRNA clones.
Of the 206 ESTs listed in the dbEST, 95% corresponded to the
full length transcript, 0.33% corresponded to transcript Type 2
and 1.7% to Type 3. The low levels of ITPA Type 2 mRNA
transcript observed in the dbESTwere in agreement with the 1%
observed for fibroblasts (Table 1). Most of the clones areented by uppercase letters and intron 2 in lowercase. The exonic splicing silencer
e uppercase font and the ITPA g.IVS2+21A>C allelic variant in blue. 5′ss are
ptic 5′ss. The 5′ ss consensus sequence cartoon has been obtained from Cartegni
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the majority of the samples analyzed in this study came from
hematopoietic tissue; reticulocytes, peripheral blood leucocytes
and EBV transformed lymphoblasts, suggesting that alternative
splicing of exons 2 and 3 is tissue or cell-type dependent.
Further studies are needed to determine levels of alternatively
spliced transcripts in various tissues from patients with different
ITPA genotypes.
In this study, fifteen individuals with six ITPA genotypes
were studied. Although three patients were homozygous for the
ITPA c.94C>A allelic variant, fewer patients with other variant
genotypes were available for study. Therefore, it would be
interesting to expand the study to gain a view of the extent of
inter-individual variation in ITPA splicing in both wild-type and
variant genotypes.
In vitro splicing studies are needed to confirm and further
explore the mechanism by which mutation in the ITPA gene
influences splicing. Expression studies are necessary to see
whether the protein encoded by the transcript lacking exons 2
and 3 has enzyme activity, is able to form functional homo- or
hetero-dimers, or is targeted to other cellular compartments.
ITPA is a candidate pharmacogenetic locus, the ITPA
c.94C>A allelic variant has been associated with adverse
drug reactions to thiopurine drug therapy [12–14]. ITPA
expression is reportedly increased in tumor cells compared to
normal tissues [30]. ITPA is over-expressed and significantly
correlated to the expression of the MLL gene, over-represented
in acute myeloid leukemia and myelodysplastic syndrome [31].
ITPA allelic variants are thus potentially relevant in carcinogen-
esis, and worthy of further study in this context.
In conclusion, the two mutations associated with ITPase
deficiency both cause mRNA missplicing. The ITPA g.IVS2+
21A>C intron mutation alters a preferred branch site resulting
in missplicing of exon 3. It is proposed that the ITPA c.94C>A
mutation causes missplicing of both exons 2 and 3 by a novel
mechanism involving the destruction of an ESS and the
activation of two cryptic 5′ss.
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